(ELV) Elevance Health - Overview
Stock: Health Insurance, Pharmacy Services, Specialty Care, Administrative Services
| Risk 5d forecast | |
|---|---|
| Volatility | 32.2% |
| Relative Tail Risk | -7.35% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.20 |
| Alpha | -18.38 |
| Character TTM | |
|---|---|
| Beta | 0.188 |
| Beta Downside | 0.219 |
| Drawdowns 3y | |
|---|---|
| Max DD | 50.38% |
| CAGR/Max DD | -0.21 |
EPS (Earnings per Share)
Revenue
Description: ELV Elevance Health January 29, 2026
Elevance Health Inc. (NYSE: ELV) is a U.S. health-benefits company organized into four operating segments-Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It delivers a full spectrum of health plans (individual, employer-group, Medicare, Medicaid, and Federal Employee Program) and ancillary products such as stop-loss, dental, vision, and supplemental insurance, while also operating a large pharmacy-services business that includes home-delivery, specialty pharmacy, formulary management, and infusion services. The firm’s technology platform, HealthOS, supports utilization management, virtual care, payment-integrity, data analytics, and post-acute care coordination, and its brands include Anthem Blue Cross & Blue Shield, Wellpoint, and Carelon.
Key recent metrics (Q4 2024 / FY 2024):
• Total revenue ≈ $152 billion, up 5 % YoY, driven by a 7 % rise in pharmacy-services revenue and continued growth in Medicare Advantage enrollment (≈ 6 % YoY).
• Membership base ≈ 115 million lives, with employer-group coverage stable and Medicaid enrollment expanding in several states following recent policy extensions.
• Adjusted EPS $4.85, net income $1.2 billion, with an operating margin of 4.5 % after integrating the Carelon acquisitions.
Sector drivers include an aging U.S. population (projected 10 % increase in Medicare-eligible adults by 2030), sustained inflation in medical-service prices (≈ 4 % annual CPI for health care), and consolidation trends in the pharmacy-benefit-management market that favor large, integrated insurers.
For a deeper, data-rich dive into Elevance’s valuation dynamics, you may find ValueRay’s analytical tools worth exploring.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 5.66b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -1.28 > 1.0 |
| NWC/Revenue: 11.03% < 20% (prev 11.32%; Δ -0.29% < -1%) |
| CFO/TA 0.04 > 3% & CFO 4.29b > Net Income 5.66b |
| Net Debt (22.55b) to EBITDA (9.66b): 2.34 < 3 |
| Current Ratio: 1.54 > 1.5 & < 3 |
| Outstanding Shares: last quarter (221.8m) vs 12m ago -4.02% < -2% |
| Gross Margin: 25.56% > 18% (prev 0.28%; Δ 2528 % > 0.5%) |
| Asset Turnover: 167.1% > 50% (prev 151.3%; Δ 15.80% > 0%) |
| Interest Coverage Ratio: 5.79 > 6 (EBITDA TTM 9.66b / Interest Expense TTM 1.40b) |
Altman Z'' 3.07
| A: 0.18 (Total Current Assets 63.00b - Total Current Liabilities 41.03b) / Total Assets 121.49b |
| B: 0.29 (Retained Earnings 35.39b / Total Assets 121.49b) |
| C: 0.07 (EBIT TTM 8.11b / Avg Total Assets 119.19b) |
| D: 0.45 (Book Value of Equity 34.94b / Total Liabilities 77.47b) |
| Altman-Z'' Score: 3.07 = A |
Beneish M -2.92
| DSRI: 1.00 (Receivables 21.54b/19.07b, Revenue 199.12b/176.81b) |
| GMI: 1.09 (GM 25.56% / 27.85%) |
| AQI: 0.87 (AQ_t 0.44 / AQ_t-1 0.51) |
| SGI: 1.13 (Revenue 199.12b / 176.81b) |
| TATA: 0.01 (NI 5.66b - CFO 4.29b) / TA 121.49b) |
| Beneish M-Score: -2.92 (Cap -4..+1) = A |
What is the price of ELV shares?
Over the past week, the price has changed by +1.14%, over one month by -10.38%, over three months by +3.10% and over the past year by -11.18%.
Is ELV a buy, sell or hold?
- StrongBuy: 13
- Buy: 5
- Hold: 4
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ELV price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 387.9 | 15.4% |
| Analysts Target Price | 387.9 | 15.4% |
| ValueRay Target Price | 339.7 | 1.1% |
ELV Fundamental Data Overview February 13, 2026
P/E Forward = 12.4688
P/S = 0.366
P/B = 1.661
P/EG = 1.2853
Revenue TTM = 199.12b USD
EBIT TTM = 8.11b USD
EBITDA TTM = 9.66b USD
Long Term Debt = 30.80b USD (from longTermDebt, last quarter)
Short Term Debt = 1.25b USD (from shortTermDebt, last quarter)
Debt = 32.05b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 22.55b USD (from netDebt column, last quarter)
Enterprise Value = 95.44b USD (72.89b + Debt 32.05b - CCE 9.49b)
Interest Coverage Ratio = 5.79 (Ebit TTM 8.11b / Interest Expense TTM 1.40b)
EV/FCF = 30.07x (Enterprise Value 95.44b / FCF TTM 3.17b)
FCF Yield = 3.33% (FCF TTM 3.17b / Enterprise Value 95.44b)
FCF Margin = 1.59% (FCF TTM 3.17b / Revenue TTM 199.12b)
Net Margin = 2.84% (Net Income TTM 5.66b / Revenue TTM 199.12b)
Gross Margin = 25.56% ((Revenue TTM 199.12b - Cost of Revenue TTM 148.22b) / Revenue TTM)
Gross Margin QoQ = 23.48% (prev 24.79%)
Tobins Q-Ratio = 0.79 (Enterprise Value 95.44b / Total Assets 121.49b)
Interest Expense / Debt = 1.14% (Interest Expense 366.0m / Debt 32.05b)
Taxrate = 15.63% (1.05b / 6.71b)
NOPAT = 6.84b (EBIT 8.11b * (1 - 15.63%))
Current Ratio = 1.54 (Total Current Assets 63.00b / Total Current Liabilities 41.03b)
Debt / Equity = 0.73 (Debt 32.05b / totalStockholderEquity, last quarter 43.88b)
Debt / EBITDA = 2.34 (Net Debt 22.55b / EBITDA 9.66b)
Debt / FCF = 7.11 (Net Debt 22.55b / FCF TTM 3.17b)
Total Stockholder Equity = 43.52b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.75% (Net Income 5.66b / Total Assets 121.49b)
RoE = 13.01% (Net Income TTM 5.66b / Total Stockholder Equity 43.52b)
RoCE = 10.92% (EBIT 8.11b / Capital Employed (Equity 43.52b + L.T.Debt 30.80b))
RoIC = 9.17% (NOPAT 6.84b / Invested Capital 74.60b)
WACC = 4.89% (E(72.89b)/V(104.93b) * Re(6.61%) + D(32.05b)/V(104.93b) * Rd(1.14%) * (1-Tc(0.16)))
Discount Rate = 6.61% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -3.01%
[DCF Debug] Terminal Value 85.07% ; FCFF base≈3.73b ; Y1≈3.31b ; Y5≈2.77b
Fair Price DCF = 277.9 (EV 83.89b - Net Debt 22.55b = Equity 61.34b / Shares 220.7m; r=5.90% [WACC]; 5y FCF grow -13.66% → 2.90% )
EPS Correlation: -31.46 | EPS CAGR: -21.49% | SUE: 0.36 | # QB: 0
Revenue Correlation: 96.17 | Revenue CAGR: 7.38% | SUE: 1.69 | # QB: 6
EPS next Quarter (2026-03-31): EPS=10.55 | Chg30d=+0.232 | Revisions Net=+1 | Analysts=19
EPS current Year (2026-12-31): EPS=26.07 | Chg30d=-0.814 | Revisions Net=-10 | Growth EPS=-13.9% | Growth Revenue=-1.4%
EPS next Year (2027-12-31): EPS=29.61 | Chg30d=-1.602 | Revisions Net=-9 | Growth EPS=+13.6% | Growth Revenue=+2.9%